171 related articles for article (PubMed ID: 21098200)
21. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
22. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
23. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas.
Mukherjee S; Ghosh SN; Chatterjee U; Chatterjee S
Neurol India; 2011; 59(6):817-22. PubMed ID: 22234191
[TBL] [Abstract][Full Text] [Related]
24. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases.
Cornelius JF; Slotty PJ; Steiger HJ; Hänggi D; Polivka M; George B
Acta Neurochir (Wien); 2013 Mar; 155(3):407-13. PubMed ID: 23318687
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical study of MRP5 expression in meningiomas.
Alexiou GA; Goussia A; Ntoulia A; Zagorianakou P; Malamou-Mitsi V; Voulgaris S; Kyritsis AP
Cancer Chemother Pharmacol; 2013 Mar; 71(3):825-8. PubMed ID: 23271324
[TBL] [Abstract][Full Text] [Related]
26. Dynamic contrast-enhanced magnetic resonance imaging perfusion characteristics in meningiomas treated with resection and adjuvant radiosurgery.
Chidambaram S; Pannullo SC; Roytman M; Pisapia DJ; Liechty B; Magge RS; Ramakrishna R; Stieg PE; Schwartz TH; Ivanidze J
Neurosurg Focus; 2019 Jun; 46(6):E10. PubMed ID: 31153141
[TBL] [Abstract][Full Text] [Related]
27. The significance of Ki-67/MIB-1 labeling index in human meningiomas: a literature study.
Abry E; Thomassen IØ; Salvesen ØO; Torp SH
Pathol Res Pract; 2010 Dec; 206(12):810-5. PubMed ID: 20951502
[TBL] [Abstract][Full Text] [Related]
28. A Magnetic Resonance comparative study between enhancement, rCBV and ACD in brain glioblastomas.
Aprile I; Muti M; Principi M; Bartolini N; Zenoni A; Tazza G; Italiani M; Ottaviano P
Radiol Med; 2002; 104(1-2):87-91. PubMed ID: 12386559
[TBL] [Abstract][Full Text] [Related]
29. High-grade and low-grade gliomas: differentiation by using perfusion MR imaging.
Hakyemez B; Erdogan C; Ercan I; Ergin N; Uysal S; Atahan S
Clin Radiol; 2005 Apr; 60(4):493-502. PubMed ID: 15767107
[TBL] [Abstract][Full Text] [Related]
30. Correlation between dynamic contrast-enhanced perfusion MRI relative cerebral blood volume and vascular endothelial growth factor expression in meningiomas.
Ginat DT; Mangla R; Yeaney G; Schaefer PW; Wang H
Acad Radiol; 2012 Aug; 19(8):986-90. PubMed ID: 22591719
[TBL] [Abstract][Full Text] [Related]
31. Magnetic resonance imaging and diffusion-weighted images of cystic meningioma: correlating with histopathology.
Chen TY; Lai PH; Ho JT; Wang JS; Chen WL; Pan HB; Wu MT; Chen C; Liang HL; Yang CF
Clin Imaging; 2004; 28(1):10-9. PubMed ID: 14996441
[TBL] [Abstract][Full Text] [Related]
32. Differentiation between benign and malignant meningiomas using diffusion and perfusion MR imaging.
Todua F; Chedia S
Georgian Med News; 2012 May; (206):16-22. PubMed ID: 22870830
[TBL] [Abstract][Full Text] [Related]
33. Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma.
Zikou AK; Alexiou GA; Kosta P; Goussia A; Astrakas L; Tsekeris P; Voulgaris S; Malamou-Mitsi V; Kyritsis AP; Argyropoulou MI
Clin Neurol Neurosurg; 2012 Jul; 114(6):607-12. PubMed ID: 22266399
[TBL] [Abstract][Full Text] [Related]
34. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
35. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.
Sugahara T; Korogi Y; Kochi M; Ikushima I; Hirai T; Okuda T; Shigematsu Y; Liang L; Ge Y; Ushio Y; Takahashi M
AJR Am J Roentgenol; 1998 Dec; 171(6):1479-86. PubMed ID: 9843274
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging.
Hakyemez B; Erdogan C; Bolca N; Yildirim N; Gokalp G; Parlak M
J Magn Reson Imaging; 2006 Oct; 24(4):817-24. PubMed ID: 16958061
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
40. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
Terzi A; Saglam EA; Barak A; Soylemezoglu F
Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
